Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
PARTNER 3: TAVR is Cost Effective Compared with SAVR for Low-Risk Patients
Author(s): David J Cohen Added: 2 years ago
Dr David J Cohen (St Francis Hospital, Roslyn, NY, US) discusses the findings from PARTNER 3 Economic Study. The study, presented first at TCT 2021, showed that for patients with severe AS and low surgical risk, TF-TAVR with the SAPIEN 3 valve is cost-saving compared with SAVR at 2-year follow-up. Discussion Points Importance of the Study Used Data Complexities in Relation to the Costs of… View more

Intervention
Author(s): Fadi J Sawaya , Lars Søndergaard Added: 3 years ago
Over the past decade, transcatheter aortic valve implantation (TAVI) has become an established and increasingly-used technique to treat patients with severe aortic valve stenosis (AS). Studies have revealed that clinical outcomes obtained with TAVI are equivalent to surgical aortic valve replacement (SAVR) in patients with a high risk profile.1,2 The Placement of Aortic Transcatheter Valves … View more

Vascular Disease and Surgery

Intervention
Research Area(s) / Expertise:

Inherited and Congenital Cardiac Conditions
Professor Lars Søndergaard is a consultant cardiologist at Rigshospitalet – Copenhagen, Denmark. Professor of Cardiology at University of Copenhagen, he published over 300 peer reviewed articles, and more than 15 textbook chapters. His research interests are focused on adults with congenital heart diseases and catheter-based heart valve interventions, as well as congenital and structural heart… View more
Author(s): Yusuke Watanabe , Makoto Nakashima Added: 3 years ago
Transcatheter aortic valve implantation (TAVI) has become a commonly used and minimally invasive approach for patients with severe aortic stenosis (AS).1,2 In the latest guidelines from the 2017 European Society of Cardiology (ESC)/European Association for Cardio-Thoracic Surgery (EACTS) for the management of valvular heart disease, the following clinical characteristics favour TAVI: Society of… View more

Vascular Disease and Surgery

Intervention
Trends in Transcatheter Aortic Valve Implantation in Australia
Author(s): Rhys Gray , Kiran Sarathy Added: 2 years ago

Intervention
ACC 2019: Corevalve low-risk TAVR Trial
Author(s): Nicolas M Van Mieghem , Michael J Reardon Added: 5 years ago
Prof Michael J Reardon (Houston Methodist, Texas, US) and Dr Nicolas van Mieghem (Rotterdam, NL) discuss the corevalve low-risk TAVR trial - self-expanding transcatheter or surgical aortic valve replacement in patients at low risk of surgical mortality. Filmed on site at ACC 2019 by Radcliffe Cardiology. Videography: Josh Birch Educational lead: Liam O'Neill (Chief Operating Officer) View more

Vascular Disease and Surgery
BCIS TAVI Statement
Author(s): Philip MacCarthy , Dave Smith , Douglas Muir , et al Added: 3 years ago

Intervention
THV
THV Summit

Broadcast

Author(s): Darren Mylotte , Lars Søndergaard , Dr Won-Keun Kim Start date: Jul 01, 2022

Intervention
ACC.24: The DEDICATE Trial
Author(s): Moritz Seiffert Added: 1 week ago
ACC.24 — Investigator Dr Moritz Seiffert (University Heart and Vascular Center Hamburg, DE) joins us onsite at ACC to discuss the findings of the DEDICATE-DZHK6 Trial (NCT03112980).This randomized controlled, multi-center trial aimed to investigate whether transcatheter aortic valve implantation (TAVI) is non-inferior to surgical aortic valve replacement (SAVR) in patients with symptomatic severe… View more

Intervention